We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $5.62B
1-Year Est. Return 36.06%
This Fund
S&P 500
This Quarter Est. Return
+1.37%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$5.76B
AUM Growth
+$5.76B
Cap. Flow
+$2.92B
Cap. Flow %
50.69%
Top 10 Hldgs %
50.49%
Holding
248
New
71
Increased
46
Reduced
39
Closed
50

Top Buys

Rank Stock Value
1
GSK icon
GSK
GSK
+$136M
2
FRPT icon
Freshpet
FRPT
+$91.3M
3
ROST icon
Ross Stores
ROST
+$81.3M
4
FIVE icon
Five Below
FIVE
+$72.6M
5
EXAS
Exact Sciences
EXAS
+$64.3M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$46.6M
2
BMY icon
Bristol-Myers Squibb
BMY
+$40.3M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$32.7M
4
UBER icon
Uber
UBER
+$32.2M
5
ORLY icon
O'Reilly Automotive
ORLY
+$31.7M

Sector Composition

Rank Sector Weight
1 Healthcare 43.44%
2 Consumer Discretionary 9.47%
3 Consumer Staples 8.21%
4 Technology 4.73%
5 Communication Services 1.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$778B
$1.2B 20.76%
+3,350,000
New +$1.33B
IWM icon
2
PUT
iShares Russell 2000 ETF
IWM
$80.9B
$594M 10.3%
+3,600,000
New +$657M
INCY icon
3
Incyte
INCY
$23.5B
$158M 2.74%
2,366,000
+366,000
+18% +$27M
SUPN icon
4
Supernus Pharmaceuticals
SUPN
$2.68B
$155M 2.7%
4,593,004
-118,996
-3% -$3.87M
PTCT icon
5
PTC Therapeutics
PTCT
$6.37B
$146M 2.53%
2,900,000
-396,000
-12% -$19.4M
TVTX icon
6
Travere Therapeutics
TVTX
$5.33B
$144M 2.49%
5,836,000
+516,000
+10% +$13.3M
NBIX icon
7
Neurocrine Biosciences
NBIX
$17.7B
$141M 2.44%
1,324,000
– –
FRPT icon
8
Freshpet
FRPT
$2.83B
$137M 2.38%
2,736,000
+1,936,000
+242% +$91.3M
MRTX
9
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$133M 2.3%
1,900,000
-148,000
-7% -$11M
ENTA icon
10
Enanta Pharmaceuticals
ENTA
$372M
$107M 1.86%
2,072,000
+2,000
+0.1% +$117K
GSK icon
11
GSK
GSK
$103B
$106M 1.84%
+3,600,000
New +$136M
ROST icon
12
Ross Stores
ROST
$76.6B
$97.6M 1.69%
1,158,117
+957,849
+478% +$81.3M
REGN icon
13
Regeneron Pharmaceuticals
REGN
$68.8B
$93.7M 1.63%
136,000
-52,000
-28% -$32.7M
DCPH
14
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$88.2M 1.53%
4,768,000
-632,000
-12% -$9.92M
PCRX icon
15
Pacira BioSciences
PCRX
$1.02B
$84.7M 1.47%
1,592,000
+1,000,000
+169% +$55.6M
ALKS icon
16
Alkermes
ALKS
$8.82B
$84.7M 1.47%
3,792,000
+868,000
+30% +$22.6M
MDGL icon
17
Madrigal Pharmaceuticals
MDGL
$12.6B
$80.3M 1.39%
1,236,000
+136,000
+12% +$9.45M
FIVE icon
18
Five Below
FIVE
$11.2B
$76.2M 1.32%
+553,231
New +$72.6M
LULU icon
19
lululemon athletica
LULU
$13B
$73.1M 1.27%
261,475
+32,902
+14% +$10.2M
ORLY icon
20
O'Reilly Automotive
ORLY
$72.4B
$70.5M 1.22%
1,503,915
-679,800
-31% -$31.7M
LOW icon
21
Lowe's Companies
LOW
$116B
$62.6M 1.09%
333,132
+195,587
+142% +$38.1M
CRSP icon
22
CRISPR Therapeutics
CRSP
$4.58B
$60.4M 1.05%
924,000
-76,000
-8% -$5.51M
BIIB icon
23
Biogen
BIIB
$29.9B
$59.8M 1.04%
224,000
-12,000
-5% -$2.55M
MDT icon
24
Medtronic
MDT
$107B
$58.5M 1.01%
724,000
-76,000
-10% -$6.83M
KYNB
25
Kyntra Bio
KYNB
$28.5M
$58M 1.01%
178,240
+14,560
+9% +$4.69M
1
2 3 4 5

Similar funds

CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return
RMDI
R.M. Davis Inc Portland, Maine $5.63B AUM 21.26% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
DWM
Diversify Wealth Management Sandy, Utah $5.61B AUM 19.63% 1-Year Est. Return
DCP
DSM Capital Partners Palm Beach Gardens, Florida $5.66B AUM 27.45% 1-Year Est. Return
EW
Evoke Wealth Los Angeles, California $5.57B AUM 23.85% 1-Year Est. Return
AIM
Alphinity Investment Management Sydney, Australia $5.68B AUM 26.72% 1-Year Est. Return
O
Ossiam Paris, France $5.69B AUM 30.95% 1-Year Est. Return

Armistice Capital's Q3 2022 Portfolio in Review

As of Q3 2022, Armistice Capital held 248 positions worth $5.76B, up 100,471% from $5.73M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Armistice Capital deployed $2.92B of net new capital in Q3 2022, opening 71 new positions and adding to 46 existing holdings. Its largest new stake was GSK: 3,600,000 shares worth $106M.

By sector, the portfolio is most concentrated in Healthcare at 43% of assets, down from 44% a quarter earlier, followed by Consumer Discretionary and Consumer Staples.

On the sell side, the largest reduction was Vertex Pharmaceuticals, an estimated $46.6M trimmed.

  • Armistice Capital's largest Q3 2022 buy was GSK: 3,600,000 shares worth $106M.
  • Armistice Capital added most to Freshpet in Q3 2022, an estimated $91.3M increase.
  • Armistice Capital's biggest Q3 2022 reduction was Vertex Pharmaceuticals, cutting an estimated $46.6M.
  • Armistice Capital fully exited State Street SPDR S&P 500 ETF Trust in Q3 2022, selling an estimated $13.3M.
  • Armistice Capital's ten largest holdings make up 50% of its $5.76B portfolio in Q3 2022.
  • Armistice Capital opened 71 new positions and closed 50 in Q3 2022.
  • Armistice Capital's portfolio value rose 100,471% quarter-over-quarter to $5.76B.

Based on Armistice Capital's 13F filing for Q3 2022, filed 14 Nov 2022.